Stockscreener 앱 받기
0.278
13.48%
-0.0433
시장 영업 전:
.29
0.012
+4.32%
전일 마감가:
$0.3213
열려 있는:
$0.291
하루 거래량:
14.54M
Relative Volume:
1.42
시가총액:
$31.99M
수익:
-
순이익/손실:
$-27.11M
주가수익비율:
-0.4277
EPS:
-0.65
순현금흐름:
$-26.55M
1주 성능:
-54.88%
1개월 성능:
-47.39%
6개월 성능:
-65.46%
1년 성능:
-84.38%
1일 변동 폭
$0.25
$0.31
1주일 범위
$0.25
$0.6678
52주 변동 폭
$0.25
$2.17
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
명칭
Reviva Pharmaceuticals Holdings Inc
전화
(408) 501-8881
주소
10080 N WOLFE ROAD, CUPERTINO
RVPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.278 | 36.97M | 0 | -27.11M | -26.55M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2023-09-20 | 개시 | ROTH MKM | Buy |
| 2023-06-08 | 개시 | The Benchmark Company | Speculative Buy |
| 2022-01-24 | 개시 | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc 주식(RVPH)의 최신 뉴스
Is Nagreeka Exports Limiteds Business Model Sustainable Long Term - earlytimes.in
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025 - ts2.tech
Reviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat
FDA recommends second phase 3 trial for Reviva’s schizophrenia drug By Investing.com - Investing.com Nigeria
Reviva considers a second phase III in schizophrenia - BioWorld MedTech
Dow Gains 100 Points; US Durable Goods Orders Decline In October - Benzinga
Why Did RVPH Stock Crash 50% Today? - Stocktwits
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial By Investing.com - Investing.com Nigeria
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial - Investing.com Nigeria
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga
Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Reviva plans second Phase 3 trial after FDA feedback - TipRanks
Reviva announces regulatory update regarding the development of brilaroxazine for the treatment of schizophrenia - marketscreener.com
Reviva Pharmaceuticals Recover-2 trial projected to cost about $60 million - marketscreener.com
FDA recommends another large trial for new schizophrenia drug - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock maintain growth trajectory2025 Fundamental Recap & Reliable Breakout Forecasts - Улправда
Profit Recap: Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionIPO Watch & Smart Swing Trading Techniques - Улправда
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue dividend increasesTrade Performance Summary & Long-Term Safe Investment Plans - Улправда
Volatility Watch: Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionTrade Exit Report & Low Risk Entry Point Tips - Улправда
Does Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock trade at a discount to peersPortfolio Value Summary & Risk Controlled Stock Alerts - Улправда
Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionWeekly Investment Report & Capital Efficiency Focused Ideas - Улправда
Will Reviva Pharmaceuticals Holdings Inc. stock attract ESG investorsNew Guidance & Capital Protection Trading Alerts - DonanımHaber
Resistance Check: Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trend2025 Key Highlights & Weekly High Momentum Picks - Улправда
Why retail investors favor Reviva Pharmaceuticals Holdings Inc. stockIPO Watch & Safe Entry Zone Tips - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. stock resist market sell offsMarket Risk Analysis & Daily Volume Surge Trade Alerts - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendWeekly Market Summary & Pattern Based Trade Signal System - Улправда
What makes Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock attractive to growth fundsJuly 2025 Momentum & Consistent Return Investment Signals - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. stock sustain institutional interestWeekly Risk Report & Real-Time Market Sentiment Alerts - Улправда
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefit from automation2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Улправда
Block Trades: Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendEarnings Growth Report & Fast Moving Stock Watchlists - Улправда
Profit Recap: Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefit from automationShare Buyback & Weekly Stock Performance Updates - Улправда
Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High - Seeking Alpha
Reviva Pharmaceuticals Holdings Inc Stock Analysis and ForecastMarket Depth Overview & Swing Trade Smarter With Data Insights - earlytimes.in
683 Capital Management LLC Makes New Investment in Reviva Pharmaceuticals Holdings, Inc. $RVPH - Defense World
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025 - ts2.tech
Stock Traders Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - MarketBeat
Published on: 2025-12-06 19:16:30 - moha.gov.vn
How supply chain issues affect Reviva Pharmaceuticals Holdings Inc. Equity Warrant stockWeekly Investment Summary & Accurate Buy Signal Alerts - Newser
Largest borrow rate increases among liquid names - TipRanks
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Are Smart Investors Making the Right Decision? Reviva Pharmaceuticals Holdings Inc (RVPH) - setenews.com
Is RVPH Positioned For NDA Submission In Schizophrenia By 2026? - RTTNews
Reviva Pharmaceuticals Holdings options imply 21.1% move in share price post-earnings - MSN
Reviva’s Schizophrenia Bet Pits Huge Upside Against Harsh Risks - Finimize
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
EBIT per share of Reviva Pharmaceuticals Holdings, Inc. Warrant 2020- 25.12.25 on Reviva Pharm – NASDAQ:RVPHW - TradingView
Reviva Pharmaceuticals Holdings Inc (RVPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
0.21%
자본화:
|
볼륨(24시간):